Specialists of the National Committee for the Coordination of anti-COVID-19 Vaccination Activities (CNCAV) state that “there are no scientific and regulatory reasons for discontinuing the vaccination with AstraZeneca.”
A debate on this topic was organized on the ‘Ro Vaccinare’ official Facebook page.
The discussion was initiated after CNCAV decided on Thursday evening that over 4,000 doses of AstraZeneca vaccine, coming from a batch for which Italy decided to temporarily suspend the administration, will be temporarily quarantined, but vaccination will continue with the serum from the other batches.
Asked what happens to people who are already scheduled for the first dose of AstraZeneca if they should go get immunized, experts say that “scientifically and legally, there is no reason to stop vaccinating with the AstraZeneca vaccine.”
“It has proven its safety profile in clinical trials. Any batch, before commercialization, must be certified in terms of quality. Thus, the risk-benefit balance is still in favor of vaccination,” they said.
Regarding quarantined batches in Europe, experts show that the European Medicines Agency continues to evaluate all reports of adverse reactions, as it normally does, and investigates thromboembolic and coagulation events reported post-vaccination.
According to the quoted source, “from the information so far,” the number of thromboembolic events “is not higher” than the usual percentage.
PM Citu: Problematic batch from AstraZeneca not distributed in Romania
Prime Minister Florin Citu said on Thursday that AstraZeneca vaccines distributed in Romania are not part of the problematic batch from Austria, following which several countries have suspended immunization with this type of serum, stressing that vaccination will continue at the same pace and the appointments for the third stage will start on March 15.
“From the information we have so far, the batch in which those few problems appeared was not distributed in Romania, so we do not have this batch in Romania. We will see what decision we will take, but the vaccination campaign goes on. We have already announced today that we will receive an additional 170,000 Pfizer doses in March, and as you know, we agreed in January to supplement the Pfizer doses by 8 million, which will start in April. So there is no problem for Romania to continue at the same pace as before the vaccination campaign. You know very well that it was a successful campaign and it is a successful campaign in Romania”, Florin Citu told B1 TV when asked about the fact that in 9 EU countries the vaccination with the serum produced by AstraZeneca has been stopped and how does this affect Romania.
The prime minister pointed out that this vaccination campaign is not made as “a title of glory”.
“We do it because the faster we vaccinate people, the more we can keep the economy open, we can afford to get back to normal faster, that’s why we do it,” the head of the Government said, according to Agerpres.
Citu confirmed that the appointments for the third stage of vaccination will start on March 15.
“We will start with third stage with everyone, so we are starting faster just to return to normal faster”, the prime minister explained.
HealthMinistry’s Baciu: Romania hasn’t received vaccines from Austria’s batch
Romania hasn’t received vaccines from the one million dose batch from which two people in Austria had been immunised and had adverse reactions, Health Ministry’s Secretary of State Andrei Baciu pointed out for AGERPRES.
“This situation has started from two adverse reactions registered in Austria, at a few days distance from the AstraZeneca vaccine shot. Consequently, the European authorities took note, they identified the vaccine batch. This vaccine batch contained one million doses, which were distributed to 17 countries in Europe, except Romania. These are Austria, Bulgaria, Cyprus, Denmark, Estonia, France, Greece, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Poland, Spain and Sweden. Moreover, following this event, some of these countries ((Estonia, Lithuania, Luxembourg, Latvia), have suspended the vaccination with the respective batch since March 9. We are talking about the vaccines that are part of the batch in question. (…) These countries suspended vaccination on March 9 with the vaccine produced by AstraZeneca, which come from the respective one million dose batch. Romania hasn’t received vaccines from the respective batch,” Baciu pointed out.
He said that the European Medicines Agency issued a statement on Thursday according to which “immunisation with vaccines produced by AstraZeneca is still recommended.”
“Based on the preliminary data and analysis, there is no causal relation between the administration of the AstraZeneca vaccine and the side effects that have occurred, but the investigation will continue. It is further recommended that the vaccine produced by AstraZeneca be administered. About 5 million doses have been administered in the EU and in Romania we are talking about 208,000 doses administered until yesterday. We are analysing and monitoring everything that is happening and we are still waiting for updates from the European Medicines Agency,” the Secretary of State added.
Olt: Doses from ABV2856 batch were used; anaphylactic shock recorded in one person
All doses of AstraZeneca vaccine from the temporarily quarantined batch (ABV 2856), distributed in Olt County, were consumed until March 3, and one person vaccinated with serum from this batch developed a severe adverse reaction and was hospitalized for over 48 hours with a favorable evolution, according to a press release of the Olt Public Health Directorate (DSP) sent to AGERPRES on Friday.
DSP Olt informed that 2,400 doses of the AstraZeneca vaccine from the ABV 2856 group have been distributed in the county since February 14, these being consumed between February 15 and March 3.
DSP Olt pointed out that currently in the county the vaccination with the serum from the other batches produced by the AstraZeneca company is continued, and there are no more doses from the temporarily quarantined batch.
Compiled from Agerpres